OpenAlex
PricingAboutJobs
Log inGet started
Work

Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival

HTML PDF

Year: 2019
Type: review
Source: Journal of Hepatology
DOI: 10.1016/j.jhep.2019.01.028
Authors: Josep M. Llovet, Robert Montal, Augusto Villanueva
Institutions: Institució Catalana de Recerca i Estudis Avançats, Hospital Clínic de Barcelona, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Tisch Cancer Institute, Universitat de Barcelona, Icahn School of Medicine at Mount Sinai
Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: hepatocellular carcinoma, surrogate endpoints, progression-free survival, time to progression, overall survival, sorafenib, lenvatinib, regorafenib, cabozantinib, ramucirumab, nivolumab, objective response rate, trial design, hazard ratio
SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Defense, Samuel Waxman Cancer Research Foundation, Cancer Research UK, European Commission, Generalitat de Catalunya, National Cancer Institute
Awards: G4119076191, G4139524798, The Tisch Cancer Institute - Cancer Center Support Grant
OpenAlex ID: W2933348020
FWCI: 3.61
Cites: 129
Cited by: 248
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms